Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

VyLibra

×

Overview

What is VyLibra?

VyLibra is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. Norgestimate is designated as (18,19-Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime,(17α)-(+)-) and ethinyl estradiol is designated as (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol).



What does VyLibra look like?



What are the available doses of VyLibra?

VyLibra consists of 28 round, biconvex tablets in the following order :

What should I talk to my health care provider before I take VyLibra?

Nursing mothers: Not recommended; can decrease milk production.  

How should I use VyLibra?

VyLibra is estrogen/progestin COCs, indicated for use by women to prevent pregnancy.

VyLibra is available in blister pack . VyLibra may be started using either a Day 1 start or a Sunday start (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.


What interacts with VyLibra?

Sorry No Records found


What are the warnings of VyLibra?

Sorry No Records found


What are the precautions of VyLibra?

Sorry No Records found


What are the side effects of VyLibra?

Sorry No records found


What should I look out for while using VyLibra?

Do not prescribe VyLibra to women who are known to have the following conditions:

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke .


What might happen if I take too much VyLibra?

There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.


How should I store and handle VyLibra?

Do not use after the expiration date.Not in-use (unopened) ADMELOG should be stored in a refrigerator (36°F-46°F [2°C-8°C]), but not in the freezer. Do not use ADMELOG if it has been frozen.In-use (opened) ADMELOG vials and ADMELOG SoloStar pens should be stored at room temperature (below 86°F [30°C]) and must be used within 28 days or be discarded, even if they still contain ADMELOG. Protect from direct heat and light.See :Do not use after the expiration date.Not in-use (unopened) ADMELOG should be stored in a refrigerator (36°F-46°F [2°C-8°C]), but not in the freezer. Do not use ADMELOG if it has been frozen.In-use (opened) ADMELOG vials and ADMELOG SoloStar pens should be stored at room temperature (below 86°F [30°C]) and must be used within 28 days or be discarded, even if they still contain ADMELOG. Protect from direct heat and light.See :Do not use after the expiration date.Not in-use (unopened) ADMELOG should be stored in a refrigerator (36°F-46°F [2°C-8°C]), but not in the freezer. Do not use ADMELOG if it has been frozen.In-use (opened) ADMELOG vials and ADMELOG SoloStar pens should be stored at room temperature (below 86°F [30°C]) and must be used within 28 days or be discarded, even if they still contain ADMELOG. Protect from direct heat and light.See :Do not use after the expiration date.Not in-use (unopened) ADMELOG should be stored in a refrigerator (36°F-46°F [2°C-8°C]), but not in the freezer. Do not use ADMELOG if it has been frozen.In-use (opened) ADMELOG vials and ADMELOG SoloStar pens should be stored at room temperature (below 86°F [30°C]) and must be used within 28 days or be discarded, even if they still contain ADMELOG. Protect from direct heat and light.See :Product: 71335-0367NDC: 71335-0367-3 28 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-1 30 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-4 6 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-5 90 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-2 60 CAPSULE, DELAYED RELEASE in a BOTTLEProduct: 71335-0367NDC: 71335-0367-3 28 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-1 30 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-4 6 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-5 90 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-2 60 CAPSULE, DELAYED RELEASE in a BOTTLEProduct: 71335-0367NDC: 71335-0367-3 28 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-1 30 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-4 6 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-5 90 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-2 60 CAPSULE, DELAYED RELEASE in a BOTTLEProduct: 71335-0367NDC: 71335-0367-3 28 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-1 30 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-4 6 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-5 90 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-2 60 CAPSULE, DELAYED RELEASE in a BOTTLEProduct: 71335-0367NDC: 71335-0367-3 28 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-1 30 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-4 6 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-5 90 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-2 60 CAPSULE, DELAYED RELEASE in a BOTTLEProduct: 71335-0367NDC: 71335-0367-3 28 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-1 30 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-4 6 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-5 90 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 71335-0367-2 60 CAPSULE, DELAYED RELEASE in a BOTTLE


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Non-Clinical Toxicology
Do not prescribe VyLibra to women who are known to have the following conditions:

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke .

Thromboembolic Disorders and Other Vascular Problems

Liver disease

High blood pressure

Carbohydrate and lipid metabolic effects:

Headache

Bleeding Irregularities and Amenorrhea

The following serious adverse reactions with the use of COCs are discussed elsewhere in labeling:

Adverse reactions commonly reported by COC users are:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).